miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells

miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression

(2015) Wenjing Mu et al.   CELL RESEARCH

miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

(2015) Marijn T. M. van Jaarsveld et al.   Molecular Cancer

Overexpression of ubiquitin carboxyl terminal hydrolase-L1 enhances multidrug resistance and invasion/metastasis in breast cancer by activating the MAPK/Erk signaling pathway

(2015) Wenjuan Wang et al.   MOLECULAR CARCINOGENESIS

Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis

(2015) L Venturutti et al.   ONCOGENE

MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer

(2015) Zhen-Hua Wu et al.   TUMOR BIOLOGY

Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway

(2015) Yubo Cao et al.   TUMOR BIOLOGY

Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells

(2013) Donghai Jiang et al.   CANCER LETTERS

Prooncogenic Factors miR-23b and miR-27b Are Regulated by Her2/Neu, EGF, and TNF-  in Breast Cancer

(2013) L. Jin et al.   CANCER RESEARCH

MicroRNAs as therapeutic targets in chemoresistance

(2013) Michela Garofalo et al.   DRUG RESISTANCE UPDATES

miR-34 – a microRNA replacement therapy is headed to the clinic

(2012) Andreas G. Bader   Frontiers in Genetics

Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice

(2011) Elisa Giovannetti et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Cancer genomics: from discovery science to personalized medicine

(2011) Lynda Chin et al.   NATURE MEDICINE

MicroRNA pharmacogenomics: Post-transcriptional regulation of drug response

(2011) Jakob Lewin Rukov et al.   TRENDS IN MOLECULAR MEDICINE

miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death

(2010) L. Galluzzi et al.   CANCER RESEARCH

MiR-199a-3p Regulates mTOR and c-Met to Influence the Doxorubicin Sensitivity of Human Hepatocarcinoma Cells

(2010) Francesca Fornari et al.   CANCER RESEARCH

MicroRNAs in ovarian cancer biology and therapy resistance

(2010) Marijn T.M. van Jaarsveld et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation

(2009) Michela Garofalo et al.   CANCER CELL

Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib

(2009) Henk J. Broxterman et al.   DRUG RESISTANCE UPDATES

Role of microRNA in anticancer drug resistance

(2009) Tongsen Zheng et al.   INTERNATIONAL JOURNAL OF CANCER

Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1)

(2009) Wang Rui et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

MicroRNAs in Cancer: Small Molecules With a Huge Impact

(2009) Marilena V. Iorio et al.   JOURNAL OF CLINICAL ONCOLOGY

The impact of microRNAs and alternative splicing in pharmacogenomics

(2009) F Passetti et al.   PHARMACOGENOMICS JOURNAL

MicroRNA and Cancer: Tiny Molecules with Major Implications

(2008) Timothy VandenBoom II et al.   CURRENT GENOMICS

The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma

(2008) Lei Chen et al.   JOURNAL OF HEPATOLOGY

MicroRNAs modulate the chemosensitivity of tumor cells

(2008) P. E. Blower et al.   MOLECULAR CANCER THERAPEUTICS